<tei xml:space="preserve">
    <teiHeader>
        <fileDesc xml:id="_0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl>

        References<lb/> 
        <bibl><label>1</label>. Ministry of Health, Labour and Welfare. Vital Statistics of Japan.<lb/> https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai18/dl/gaikyou30.pdf.<lb/> Accessed 25 March 2020.<lb/> </bibl>
        <bibl><label>2</label>. National Cancer Center Japan. Cancer Statistics in 2016.<lb/> https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2019_report.pdf. Accessed 29 June<lb/> 2019.<lb/> </bibl>
        <bibl><label>3</label>. Ministry of Health, Labour and Welfare. Estimated number of patients.<lb/> https://www.mhlw.go.jp/toukei/saikin/hw/kanja/17/dl/01.pdf. Accessed 25 August 2020.<lb/> </bibl>
        <bibl><label>4</label>. Japanese Society of Medical Oncology. Guidelines for Cancer Immunotherapy. 2nd ed.<lb/> Tokyo, Japan: Kanehara &amp; Co., Ltd.; 2019.<lb/> </bibl>
        <bibl><label>5</label>. Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC, Naidoo J,<lb/> Moslehi JJ. Immune checkpoint inhibitor toxicities: systems-based approaches to improve<lb/> patient care and research. Lancet Oncol. 2020;21(8):e398-e404.<lb/> https://doi.org/10.1016/S1470-2045(20)30107-8<lb/> </bibl>
        <bibl><label>6</label>. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with<lb/> immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168.<lb/> https://doi.org/10.1056/NEJMra1703481<lb/> </bibl>
        <bibl><label>7</label>. Tadano H, Torigoe T. Immune-related adverse events of immune checkpoint inhibitors.<lb/> Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(2):102-108.<lb/> https://doi.org/10.2177/jsci.40.102<lb/> </bibl>
        <bibl><label>8</label>. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa<lb/> L, Davies M, Dunnington D, Ernstoff MS. Management of immunotherapy-related<lb/> J o u r n a l P r e -p r o o f<lb/> toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr<lb/> Canc Netw. 2019;17(3):255-289. https://doi.org/10.6004/jnccn.2019.0013<lb/> </bibl>
        <bibl><label>9</label>. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I,<lb/> Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S. Management of immune-related adverse<lb/> events in patients treated with immune checkpoint inhibitor therapy: American Society of<lb/> Clinical Oncology clinical practice guideline. Journal Clin Oncol. 2018;36(17):1714-1768.<lb/> https://doi.org/10.1200/jco.2017.77.6385.<lb/> </bibl>
        <bibl><label>10</label>. Kagamu H, Yamaguchi O, Todo M, Tamaki S. チームで取り組む免疫チェックポイン<lb/> ト阻害薬治療 [A team approach to immune checkpoint inhibitor therapy]. Tokyo, Japan:<lb/> Chugai-Igakusha; 2019.<lb/> </bibl>
        <bibl><label>11</label>. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y,<lb/> Tanaka K, Takeda M, Nakagawa K. Association of immune-related adverse events with<lb/> nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374-378.<lb/> https://dx.doi.org/10.1001/jamaoncol.2017.2925<lb/> </bibl>
        <bibl><label>12</label>. Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M,<lb/> Borgonovo K, Parati MC, Tomasello G. Immune-related adverse events and survival in solid<lb/> tumors treated with immune checkpoint inhibitors: A systematic review and meta-analysis. J<lb/> Immunother. 2020;43(1):1-7. https://doi.org/10.1097/CJI.0000000000000300<lb/> </bibl>
        <bibl><label>13</label>. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C,<lb/> Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec<lb/> J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A,<lb/> Marabelle A. Management of immune checkpoint blockade dysimmune toxicities: a<lb/> collaborative position paper. Ann Oncol. 2016;27(4):559-574. doi:10.1093/annonc/mdv623<lb/></bibl>
        <bibl><label>14</label>. Hayashi C, Kokufu H. The status of nursing practice for cancer patients receiving<lb/> chemotherapy and factors related to the practice of nursing. J Jpn Soc Cancer Nurs.<lb/> 2010;24(3);33-44.<lb/> </bibl>
        <bibl><label>15</label>. Moto N. チーム医療の現状と今後の展望 [Current status and prospects of the team<lb/> approach to medicine]. J Jpn Soc Clin Oncol. 2014;49(2);489-492.<lb/> </bibl>
        <bibl><label>16</label>. Melnyk BM, Fineout-Overholt E, Feinstein NF, Li H, Small L, Wilcox L, Kraus R. Nurses&apos;<lb/> perceived knowledge, beliefs, skills, and needs regarding evidence-based practice:<lb/> Implications for accelerating the paradigm shift. Worldviews Evid-Based Nurs.<lb/> 2004;1(3):185-193. https://doi.org/10.1111/j.1524-475X.2004.04024.x<lb/> </bibl>
        <bibl><label>17</label>. Ministry of Health, Labour and Welfare. Designated cancer hospital.<lb/> https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/gan/gan_byoin.htm<lb/> l. Accessed 2 August 2020.<lb/> </bibl>
        <bibl><label>18</label>. Ministry of Health, Labour and Welfare. [Guidelines for the promotion of optimal use].<lb/> https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-<lb/>Iyakushokuhinkyoku/0000162318.pdf. Accessed 1 October 2022.<lb/> </bibl>
        <bibl><label>19</label>. Oda T. [The Fundamentals of Social Research Methods]. Tokyo, Japan: Pleiades Publishing<lb/> Co., Ltd.; 2017.<lb/> </bibl>
        <bibl><label>20</label>. Nivolumab [Guidelines for Optimal Use]. New York, NY: Bristol-Myers Squibb Company;<lb/> 2014.<lb/> </bibl>
        <bibl><label>21</label>. Pembrolizumab [Guidelines for Optimal Use]. Kenilworth, NJ: Merck &amp; Co., Inc; 2017.<lb/> </bibl>
        <bibl><label>22</label>. Wang DY, Salem J, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann<lb/> KE, Ha L, Rathmell WK. Fatal toxic effects associated with immune checkpoint inhibitors:<lb/> A systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721-1728.<lb/> https://doi.org/10.1001/jamaoncol.2018.3923.<lb/> </bibl>
        <bibl><label>23</label>. Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for<lb/> patient monitoring and management of immune-mediated adverse events. Immunotargets<lb/> Ther. 2017;6:51-71. https://doi.org/10.2147/ITT.S141577<lb/> </bibl>
        <bibl><label>24</label>. El Majzoub I, Qdaisat A, Thein KZ, Chandra S, Menzer C, Ye F, Zhao S, Das S,<lb/> Beckermann KE, Ha L, Rathmell WK. Adverse effects of immune checkpoint therapy in<lb/> cancer patients visiting the emergency department of a comprehensive cancer center. Ann<lb/> Emerg Med. 2019;73(1):79-87. https://doi.org/10.1016/j.annemergmed.2018.04.019<lb/> </bibl>
        <bibl><label>25</label>. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I,<lb/> Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S. Management of immune-related adverse<lb/> events in patients treated with immune checkpoint inhibitor therapy: American Society of<lb/> Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768.<lb/> https://doi.org/10.1200/jco.2017.77.6385<lb/> </bibl>
        <bibl><label>26</label>. Kurata T, Yosioka H, Kaneda T. 肺がん化学療法 副作用マネジメント [Side effect<lb/> management for lung cancer chemotherapy]. Tokyo: Medical View Co., Ltd.; 2019.<lb/> </bibl>
        <bibl><label>27</label>. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J<lb/> Health Promot. 1997;12(1):38-48. https://doi.org/10.4278/0890-1171-12.1.38. PMID:<lb/> 10170434<lb/> </bibl>
        <bibl><label>28</label>. Japanese Nursing Association. Nursing Statistics.<lb/> https://www.nurse.or.jp/home/statistics/index.html. Accessed 27 January 2021.<lb/> </bibl>
        <bibl><label>29</label>. Kikuchi A, Harada T. A study on the measurement of professional autonomy in nursing.<lb/> Bulletin of the Education Faculty, Shizuoka University. Liberal Arts and Social Sciences<lb/> Series. 1996;47:241-254.<lb/> </bibl>
        <bibl><label>30</label>. The Japanese Respiratory Society. 薬剤性肺障害の診断・治療の手引き短縮版 2013<lb/> [Guide to the diagnosis and treatment of drug-induced lung disorders shortened edition<lb/> 2013]. https://www.jrs.or.jp/uploads/uploads/files/photos/1049.pdf. Accessed 20 January<lb/> 2021.<lb/> </bibl>
        <bibl><label>31</label>. Wood LS, Moldawer NP, Lewis C. Immune checkpoint inhibitor therapy: Key principles<lb/> when educating patients. Clin J Oncol Nurs. 2019;23(3):271-280.<lb/> https://doi.org/10.1188/19.CJON.271-280.<lb/> </bibl>
        <bibl><label>32</label>. McGettigan S, Rubin KM. PD-1 inhibitor therapy: Consensus statement from the faculty of<lb/> the Melanoma Nursing Initiative on managing adverse events. Clin J Oncol Nurs. 2017;21(4<lb/> Suppl):42-51. https://doi.org/10.1188/17.CJON.S4.42-51<lb/> </bibl>
        <bibl><label>33</label>. Londoño M, Reig M. Multidisciplinary clinical approach to cancer patients with immune-<lb/>related adverse events induced by checkpoint inhibitors. Cancers (Basel). 2020;12(11):3446.<lb/> https://doi.org/10.3390/cancers12113446</bibl>
        </listBibl>
    </text>
</tei>
